Ensitrelvir
Modify Date: 2024-01-03 11:29:00
Ensitrelvir structure
|
Common Name | Ensitrelvir | ||
|---|---|---|---|---|
| CAS Number | 2647530-73-0 | Molecular Weight | 531.88 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H17ClF3N9O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of EnsitrelvirEnsitrelvir (S-217622) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM)[1][2]. |
| Name | 1,3,5-Triazine-2,4(1H,3H)-dione, 6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]dihydro-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-, (6E)- |
|---|
| Description | Ensitrelvir (S-217622) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM)[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | In a cytopathic effect (cpe)-inhibition assay of SARS-CoV-2 infected VeroE6/TMPRSS2 cells, Ensitrelvir shows the EC50 values are approximately 0.4 μM for both wild-type virus and Alpha, Beta, Gamma and Delta variants. EC50 values for SARS-CoV and MERS-CoV were 0.21 and 1.4 μM respectively[1]. |
| In Vivo | Ensitrelvir dose-dependently inhibits intrapulmonary replication of SARS-CoV-2 in mice[2]. |
| References |
| Molecular Formula | C22H17ClF3N9O2 |
|---|---|
| Molecular Weight | 531.88 |